IMRX - NASDAQ

Immuneering Corporation

IMRX·NASDAQ

$4.55

+3.4%

HealthcareBiotechnology

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$165.18M

EPS-1.2700

P/E Ratio-3.58

Earnings Date08/12/2026

imrx

Net Cash Provided by Financing Activities

Last Annual Value

226.58M

3-Year CAGR

2185%

5-Year CAGR

43%

10-Year CAGR

29%

Adjust for Inflation

Immuneering Corporation Competitors Analysis of Net Cash Provided by Financing Activities

IMRX · NASDAQ

Company	Net Cash Provided by Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Immuneering Corporation NASDAQ:IMRX	226.58M	99.7%	9.4%	N/A
Foghorn Therapeutics Inc. NASDAQ:FHTX	1.02M	-16.8%	-46.1%	N/A
Humacyte, Inc. NASDAQ:HUMA	61.49M	138.9%	-25.4%	N/A
Codexis, Inc. NASDAQ:CDXS	27.93M	50.7%	49.3%	N/A
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	77.43M	N/A	4.9%	16.5%
Neonc Technologies Holdings, Inc. NASDAQ:NTHI	20.86M	153.6%	142.3%	N/A
Cassava Sciences, Inc. NASDAQ:SAVA	-239.00K	N/A	N/A	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	70.75M	69.3%	16.6%	70.7%
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	86.30M	57.0%	48.2%	9.7%
Protara Therapeutics, Inc. NASDAQ:TARA	82.72M	N/A	N/A	82.0%
Nautilus Biotechnology, Inc. NASDAQ:NAUT	214.00K	-16.5%	-76.9%	N/A

Immuneering Corporation Fair Value Envelope

IMRX · NASDAQ

Our analysis suggests that IMRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.55, this represents a potential HIDDEN relative to our calculated worth for Immuneering Corporation.

HIDDEN

Intrinsic Value

Current Price: $4.55

Related Guides

Blog Categories

Continue your IMRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.